US-based MMRGlobal (MMR) will receive two additional US patents covering methods of making compositions for its B-cell vaccine technologies.
The patent entitled 'Method and Composition for Altering a B-cell Mediated Pathology', will be the fourth US manufacturing patent that covers the methods of making compositions for B-cell vaccines used in the fight against lymphoma and potentially other forms of cancer.
MMR is a provider of Personal Health Records (PHRs), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals.
The company had also secured a notice of allowance in Mexico for protecting the same technology, entitled 'Method and Composition for Altering a B-cell Mediated Pathology' and will be the third issued patent in Mexico to protect this technology.
Earlier this month, the company had also filed a divisional application involving similar technology to retain another pending application with the Japanese Patent Office.
